ReproNovo Announces First Participant Included in U.S. Phase 2 Trial of RPN-001 for Male Infertility
RPN-001 is a novel orally administered aromatase inhibitor being developed for the treatment of infertility in men with low serum testosterone No FDA-approved oral therapies currently exist for this underserved population LAUSANNE, Switzerland and COPENHAGEN, Denmark, July 01, 2025 (GLOBE NEWSWIRE) — ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine and women's […]